XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases

mAbs

Volumn 3, Issue 1, 2011, Pages 49-60

  Owyang, Alexander M ^a,b   Issafras, Hassan ^a   Corbin, John ^a   Ahluwalia, Kiran ^a   Larsen, Paul ^a,c   Pongo, Elizabeth ^a   Handa, Masahisa ^a   Horwitz, Arnold H ^a   Roell, Marina K ^a   Haak Frendscho, Mary ^a,d   Masat, Linda ^a,d  

^a XOMA Corporation   (United States)

^b RIGEL PHARMACEUTICALS INC   (United States)

^c ARRAY BIOPHARMA INC   (United States)

^d Takeda San Francisco   (United States)

Author keywords

Affinity; Autoimmune disease; Gevokizumab; Gout; IL 1 ; Inflammation; Therapeutic antibody

Indexed keywords

EPITOPE; GEVOKIZUMAB; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; CONTROLLED STUDY; GOUT; HALF LIFE TIME; IN VITRO STUDY; IN VIVO CULTURE; IN VIVO STUDY; INFLAMMATION; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; PERITONITIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CELL LINE; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; FIBROBLASTS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; KINETICS; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 78651389288     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.1.13989     Document Type: Article

References (40)

1. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-147; PMID: 8630372.
2. Lichtman AH, Chin J, Schmidt JA, Abbas AK. Role of interleukin 1 in the activation of T lymphocytes. Proc Natl Acad Sci USA 1988; 85:9699-703; PMID: 3264404.
3. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998; 16:457-99; PMID: 9646173.
4. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201:1479-86; PMID: 15851489.
5. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005; 52:1283-6; PMID: 15818707.
6. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50:607-12; PMID: 14872505.
7. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005; 52:1960-7; PMID: 15986340.
8. Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002; 41:972-80; PMID: 12209029.
9. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851-60; PMID: 12235117.
10. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-26; PMID: 17429083.
11. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203:1685-91; PMID: 16818675.
12. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-7; PMID: 17676044.
13. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942-9; PMID: 17676045.
14. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677-88; PMID: 16782025.
15. Masat L, Haak-Frendscho M, Chen G, Horwitz AH, Roell MK. IL-1β binding antibodies and fragments thereof. May 12, 2009. US Patent 7,531,116.
16. Studnicka GM, Soares S, Better M, Williams RE, Nadell R, Horwitz AH. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng 1994; 7:805-14; PMID: 7937712.
17. Owyang AM, Maedler K, Gross L, Yin J, Esposito L, Shu L, et al. XOMA 052, an anti-IL-1beta monoclonal antibody, improves glucose control and beta-cell function in the diet-induced obesity mouse model. Endocrinology 2010; 151:2515-27; PMID: 20332197.
18. Roell MK, Issafras H, Bauer RJ, Michelson KS, Mendoza N, Vanegas SI, et al. A kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1 beta (IL-1β) activity. J Biol Chem 2010; PMID: 20410301.
19. Drake AW, Myszka DG, Klakamp SL. Characterizing High Affinity Antibody/Antigen Complexes. In: Shire SJGW, Bechtold-Peters K, Andya J, Ed. Current Trends in Monoclonal Antibody Development and Manufacturing: Springer, AAPS Press 2010; 179-92; DOI: 10.1007/978-0-387-76643-0-11.
20. Rathanaswami P, Roalstad S, Roskos L, Su QJ, Lackie S, Babcook J. Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. Biochem Biophys Res Commun 2005; 334:1004-13; PMID: 16038881.
21. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG. Analyzing a kinetic titration series using affinity biosensors. Anal Biochem 2006; 349:136-47; PMID: 16337141.
22. Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature 1997; 386:190-4; PMID: 9062193.
23. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-41; PMID: 16407889.
24. Gallis B, Prickett KS, Jackson J, Slack J, Schooley K, Sims JE, et al. IL-1 induces rapid phosphorylation of the IL-1 receptor. J Immunol 1989; 143:3235-40; PMID: 2530274.
25. Punzi L, Pozzuoli A, Pianon M, Bertazzolo N, Oliviero F, Scapinelli R. Pro-inflammatory interleukins in the synovial fluid of rheumatoid arthritis associated with joint hypermobility. Rheumatology (Oxford) 2001; 40:202-4; PMID: 11257158.
26. Donath M. XOMA 052, an anti-IL1b antibody, in a double-blind, placebo-controlled, dose excalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus - A new approach to therapy. Diabetologia 2008; 51:1-7.
27. Grutter MG, van Oostrum J, Priestle JP, Edelmann E, Joss U, Feige U, et al. A mutational analysis of receptor binding sites of interleukin-1beta: differences in binding of human interleukin-1beta muteins to human and mouse receptors. Protein Eng 1994; 7:663-71; PMID: 8073036.
28. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:28; PMID: 17352828.
29. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68:1613-7; PMID: 19635719.
30. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62:3064-76; PMID: 20533546.
31. Mills KH, Dunne A. Immune modulation: IL-1, master mediator or initiator of inflammation. Nat Med 2009; 15:1363-4; PMID: 19966773.
32. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6:232-41; PMID: 20177398.
33. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464:1357-61; PMID: 20428172.
34. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010; 6:158-66; PMID: 20173777.
35. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10:89-102; PMID: 20081871.
36. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41:2196-204; PMID: 9870876.
37. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:614-24; PMID: 11920396.
38. Owyang AM, Vanegas S, Gross L, Masat E, Pongo P, Larsen J, et al. Kantak efficacy of XOMA 052 anti-IL-1beta antibody in the dba/1 mouse collagen-induced arthritis model. The European League Against Rheumatism. Paris, France: Ann Rheum Dis 2008; 591.
39. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, et al. The human anti-IL-1beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10:67; PMID: 18534016.
40. Dinarello CA, Ed. Cytokines and their cellular receptors, Current Protocols in Immunology. New York: Wiley 2000; 6:1-7.